News

1 2 3 4 5 6 7 8 12 17 22
NEWS

Oral Presentation of Interim Data from the AURELIO-03 Study of SOT101 at the 2022 ASCO Annual Meeting

  • SOTIO will share interim safety and efficacy results from SOTIO’s AURELIO-03 study on Saturday, June 4
  • AURELIO-03 is a Phase 1/1b dose escalation study of the interleukin-15 superagonist SOT101 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it will deliver an oral presentation featuring interim safety and efficacy data from the Phase 1/1b AURELIO-03 study with its IL-15 superagonist, SOT101, as monotherapy and in combination with pembrolizumab at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2022, taking place in Chicago, Illinois from June 3-7, 2022.

NEWS

SOTIO Announces Oral and Multiple Poster Presentations on Key Clinical Programs at the American Association of Cancer Research Annual Meeting (AACR) 2022

  • Oral presentation will focus on interim efficacy and safety data from the Phase 1/1b AURELIO-03 study of SOT101 in combination with pembrolizumab
  • Poster presentations will feature preclinical data on SOTIO’s immunocytokine SOT201 and the BOXR CAR-T cell therapy BOXR1030

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it will deliver an oral presentation featuring interim safety and efficacy data from its Phase 1/1b AURELIO-03 study with its IL-15 superagonist, SOT101, in combination with pembrolizumab, as well as two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, taking place in New Orleans, Louisiana, April 8-13, 2022.

NEWS

SOTIO Announces Clinical Collaboration with MSD to evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

  • The Phase 2 AURELIO-04 study is expected to enroll up to 300 patients across six different indications
  • The study will be conducted in the US and selected European countries and will begin in the first half of 2022

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., through its subsidiaries, to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® (pembrolizumab) in patients with selected advanced/refractory solid tumors in the phase 2 AURELIO-04 study.